There are currently four patents that relate to the ingredients in NeuroGenesis products. Patent disclosures and claims are typically loaded with advanced scientific and legal languages. Below is a simple brief overview of just two of our patents to help you acquire preliminary understanding.
The significance of the words contained in these Patents is usually determined by Federal Courts of Law and made secure by Federal Courts of Appeal. The first two patents have been adjudicated in the 3rd Federal Court of Appeals (highest appellet court for patent defense).
Please note: A patent grant does not indicate that a product is safe or useful for any health-associated application. Many patents are granted for chemical products which cannot be marketed because they are not safe, or are only marginally effective. However, a use patent is the exclusive right to use a substance in a specific way.
The result of court case involved is that the coverage of these two portents was defined as follows:
- Patent No. 4,761,429 is construed as including any preparation using D-phenylalanine or any effective combination of the following ingredients: D-phenylalanine, D/L-phenylalanine, D-leucine; D/L-leucine; and hydrocinnamic acid (folic acid), in the treatment or prevention of alcoholism, narcotic addiction and/or the treatment or prevention of cravings for alcohol and/or narcotics. This Patent is construed as including any preparation containing such ingredients used for the treatment or prevention of cravings for excessive amounts of foods containing carbohydrates; stress and stress-induced damage; ADD (attention deficit disorders) and AD/HD (attention deficit hyperactivity disorders) and other disorders that are related to neurotransmitter insufficiencies.
- Patent No. 5,189,064 is interpreted to include, among its other claims, a composition used for the treatment of cocaine addictions and/or to reduce cravings for narcotics, including cocaine, consisting of
- hydrocinnamic acid (folic acid), any D-form mono amino acid, D-phenylalanine, and/or D/L-phenylalanine; and
- L-glutamic acid, L-glutamic, and/or L-glutamine and/or L-tryptophan (or a substitute).
The '064 Patent is also construed as including any preparation containing such ingredients used for the treatment or prevention of cravings for excessive amounts of foods containing carbohydrates; stress and stress-induced organ damage, attention deficit disorders and attention deficit hyperactivity disorders and other disorders that are related to neurotransmitter insufficiencies."
In short, the Patents are not adjudicated on ingredients; they are "use Patents." Any formulation containing D- or D/L-phenylalanine or any other enkephalinase inhibitor when used for the nutritional support or prevention of cravings for alcohol, drugs, carbohydrates, for stress related disorders or for ADD or AD/HD, is covered by the Patent '429. Further, Patent '064 states that the formulation is further augmented by the addition of L-glutamine or L-tryptophan precursor (or a substitute).
The complete story can, of course, be obtained from the claims at the back of each of the patents.
The United States patent numbers are:
- No. 4,761,429
- No. 5,189,064
- No. 5,922,361
- No. 6,159,506
More information...
